Method for Treating Cancers with Dendritic Killer Cells and Pharmaceutical Composition
The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is IL-15. Meanwhile a pharmaceutical composition comprises the above dendritic killer cell population for treating cancers is also disclosed in the present invention.
1 . A pharmaceutical composition for treating cancers comprising an effective medical dosage of dendritic killer cell population and a buffer fitted in with cellular acceptance, wherein the dendritic killer cell population is generated by culturing with cytokines.
2 . The pharmaceutical composition according to claim 1 , wherein the dendritic killer cell population comprises surface markers of HLA-G − CD14 − CD19 − CD3 − CD56 + HLA-DR + .
3 . The pharmaceutical composition according to claim 1 , wherein the buffer can be selected from a group consisting of phosphate buffer and saline solution.
4 . The pharmaceutical composition according to claim 1 , wherein the cytokines comprises an effective amount of IL-15.
5 . The pharmaceutical composition according to claim 4 , wherein the cytokines further comprises an effective amount of IL-12.
6 . The pharmaceutical composition according to claim 1 , wherein dendritic killer cell population is generated ex vivo by culturing dendritic killer cells of human blood with the cytokines.
7 . The pharmaceutical composition according to claim 6 , wherein the human blood is collected from a cancer patient.
8 . The pharmaceutical composition according to claim 7 , the pharmaceutical composition is administered to the cancer patient for inhibiting the tumor growth.
9 . The pharmaceutical composition according to claim 1 , the pharmaceutical composition is transferred through injection.
10 . A use of dendritic killer cell population for manufacturing medication, wherein the medication is applied for treating cancer and the dendritic killer cell population is generated by culturing with at least a cytokine.
11 . The use according to claim 10 , wherein the medication is administered to a cancer patient for inhibiting the tumor growth.
12 . The use according to claim 10 , wherein the cytokine comprises an effective amount of IL-15.
13 . The use according to claim 12 , wherein the cytokine further comprises an effective amount of IL-12.
14 . The use according to claim 10 , wherein the dendritic killer cell population can form a pharmaceutical composition with a buffer.
15 . A method for treating cancers comprising the following steps:
obtaining dendritic killer cells from a cancer patient;
generating a dendritic killer cell population by culturing the dendritic killer cells; and
delivering the dendritic killer cell population into the cancer patient.
16 . The method according to claim 15 , wherein the dendritic killer cell population is obtained by culturing the dendritic killer cells with at least a cytokine.
17 . The method according to claim 16 , wherein the cytokine comprises IL-15.
18 . The method according to claim 17 , wherein the cytokine further comprises IL-12.
19 . The method according to claim 15 , wherein the dendritic killer cell population is collecting from human blood of the cancer patient.
20 . The method according to claim 15 , wherein the dendritic killer cell population is administered to the cancer patient through intravenous injection.
21 . A pharmaceutical composition containing a plurality of human DKCs, wherein the DKCs are HLA-G − CD14 − CD19 − CD3 − CD56 + HLA-DR + .
22 . A method of treating a tumor in a human subject in need thereof, the method comprising administering to the human subject the composition of claim 1 .
23 . A method of treating a tumor in a human subject in need thereof, the method comprising administering to the human subject the composition of claim 21 .